Continuous lenalidomide treatment for newly diagnosed multiple myeloma

Clicks: 357
ID: 269069
2012
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
MPR-R significantly prolonged progression-free survival in patients with newly diagnosed multiple myeloma who were ineligible for transplantation, with the greatest benefit observed in patients 65 to 75 years of age. (Funded by Celgene; MM-015 ClinicalTrials.gov number, NCT00405756.).
Reference Key
a2012thecontinuous Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Palumbo A;Hajek R;Delforge M;Kropff M;Petrucci MT;Catalano J;Gisslinger H;Wiktor-Jędrzejczak W;Zodelava M;Weisel K;Cascavilla N;Iosava G;Cavo M;Kloczko J;Bladé J;Beksac M;Spicka I;Plesner T;Radke J;Langer C;Ben Yehuda D;Corso A;Herbein L;Yu Z;Mei J;Jacques C;Dimopoulos MA; ;;
Journal The New England journal of medicine
Year 2012
DOI
DOI not found
URL
Keywords
Administration National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't female male aged Comparative Study 80 and over Clinical Trial Phase III Randomized Controlled Trial Double-Blind Method Multicenter Study follow-up studies neutropenia / chemically induced induction chemotherapy antineoplastic combined chemotherapy protocols / adverse effects disease-free survival prednisone / adverse effects oral neoplasms kaplan-meier estimate maintenance chemotherapy antineoplastic combined chemotherapy protocols / therapeutic use* prednisone / administration & dosage* initials='g' affs=[] is_editor=false suffix=none equal_contrib=false) initials='jp' initials='ag' initials='j' initials='a' initials='h' initials='am' initials='b' initials='n' initials='p' initials='k' author(firstnames='j' author(firstnames='g' author(firstnames='h' author(firstnames='a m' author(firstnames='p' author(firstnames='a' initials='d' affs=[]) initials='s' initials='m' initials='o' initials='f' initials='i' initials='r' initials='e' initials='v' author(firstnames='s' author(firstnames='n' author(firstnames='t' initials='t' author(firstnames='m' author(firstnames='d' author(firstnames='e' author(firstnames='k' author(firstnames='r' author(firstnames='v' initials='fj' initials='js' initials='ml' initials='z' equal_contrib=false)] lastname='mollee' lastname='prince' lastname='horvath' lastname='greil' lastname='van droogenbroeck' lastname='schots' author(firstnames='f' author(firstnames='z' author(firstnames='i' author(firstnames='o' pmid:22571200 doi:10.1056/nejmoa1112704 antonio palumbo roman hajek collabauthor(name='mm-015 investigators' investigators=[author(firstnames='b' lastname='augustson' lastname='joshua' lastname='spencer' lastname='taylor' author(firstnames='a g' lastname='gastl' lastname='ludwig' lastname='iskrov' lastname='uss' lastname='fillet' lastname='maisnar' lastname='scudla' lastname='gregersen' lastname='attal' author(firstnames='j p' lastname='fermand' lastname='jaccard' lastname='macro' author(firstnames='j -f' lastname='rossi' initials='j-' lastname='dölken' lastname='engelhardt' lastname='goldschmidt' lastname='knop' lastname='niederwieser' lastname='crotty' lastname='nagler' lastname='rowe' lastname='shpilberg' lastname='cafro' lastname='caravita' lastname='foa' lastname='gobbi' lastname='zweegman' lastname='dmoszynska' lastname='hellmann' author(firstnames='a b' lastname='skotnicki' initials='ab' lastname='abdulkadyrov' lastname='domnikova' lastname='osmanov' lastname='rossiev' lastname='rukavistin' lastname='alegre' author(firstnames='f j' lastname='capote' author(firstnames='m l' lastname='martino' author(firstnames='j s' lastname='miguel' lastname='ahlgren' lastname='bauer' lastname='stenner' lastname='cagirgan' lastname='schey' lastname='yong' lastname='kaplan' lastname='kyeting' lastname='lysa' lastname='maslyak' lastname='pylypenko' lastname='tretyak' lenalidomide melphalan / administration & dosage* melphalan / adverse effects multiple myeloma / drug therapy* multiple myeloma / mortality second primary / epidemiology thalidomide / administration & dosage thalidomide / adverse effects thalidomide / analogs & derivatives*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.